Sign in Subscribe
Sustainable development

Estimating Cancer Patients Eligible for Hadron Therapy in the SEE Region

Strategic Insights

— 2 min read

A new report presents research on sustainability in the field of oncology, focusing on the establishment of the South-East European International Institute for Sustainable Technologies (SEEIIST) to provide cutting-edge Hadron radiation therapy treatment. To justify the initiative, researchers estimated the number of patients with cancer from the SEE region eligible for Hadron therapy (HT) using two methods: the International Agency on Research on Cancer (IARC) World Health Organization's (WHO) Globocan model and a linear regression model. The study found that approximately 2900 to 3200 patients per year would be eligible for HT in the new SEEIIST facility in 2030.

Key Takeaways:

  • The SEEIIST initiative will provide a cutting-edge Hadron radiation therapy treatment and research institute for treating cancer patients with Hadron therapy (HT).
  • The study used two methods to estimate the number of patients with cancer from the SEE region eligible for HT: the IARC WHO's Globocan model and a linear regression model.
  • Cancer epidemiology data were collected and studied by using the countries' cancer datasheets from WHO.
  • The top 10 cancers were presented for the SEE region.
  • The study developed a primordial model for estimating the number of SEE patients who could be treated most successfully with HT upon SEEIIST commissioning in 2030.
  • It is estimated that 2900 to 3200 patients per year would be eligible for HT in the new SEEIIST facility in 2030.
  • The SEEIIST will initially treat approximately 400 patients per year, progressing toward 1000.
  • The creation of SEEIIST dedicated patient selection criteria will be both necessary and highly challenging.
  • The study included data from countries in the SEE region, such as North Macedonia, where the research was conducted by PhD Mimoza M. Ristova and colleagues.
  • The study's findings can inform the development of the SEEIIST facility and its treatment capabilities.

Statistics:

  • 2900-3200 patients per year would be eligible for Hadron therapy in the new SEEIIST facility in 2030.
  • The SEEIIST will initially treat approximately 400 patients per year.
  • The facility will progress to treat 1000 patients per year.
  • The top 10 cancers presented for the SEE region.

Sources:

  • [1] Patients With Cancer in the Countries of South-East Europe (the Balkans) Region and Prospective of the Particle Therapy Center: South-East European International Institute for Sustainable Technologies. Advances in Radiation Oncology, 2021,6(6):100772. (Advances in Radiation Oncology - http://www.journals.elsevier.com/advances-in-radiation-oncology/).
  • [2] NewsRx. Findings from Physics Department Broaden Understanding of Sustainability Research [Patients With Cancer in the Countries of South-East Europe (the Balkans) Region and Prospective of the Particle Therapy Center: South-East European International ...]. Health & Medicine Week. November 26, 2021; p 1989.

Read more